Borrelia garinii and Borrelia bavariensis are European and Asian species of the Lyme-causing Borrelia complex. Both have been confirmed in Ixodes holocyclus — the paralysis tick, native and endemic to the east coast of Australia — by CSIRO research. The VlsE surface protein rotation mechanism is identical to that of the North American Borrelia burgdorferi. The tick vector exists. The pathogen exists. The mechanism by which it evades detection (VlsE rotation causing false negatives on standard serology) is the same. Australian patients presenting with Lyme-like symptoms — fatigue, joint pain, cognitive dysfunction, cardiac symptoms after a tick bite — who test negative on Australian two-tier serology, are told: you don't have Lyme. The DOH position says: there is no Lyme in Australia. Both statements are false. The pathogen is present. The serology is unreliable for the same reasons it is unreliable in Ontario. The patients are not imagining their illness. They are living with an untreated infection that their own government has officially declared doesn't exist. Patients who can afford it fly to California, Germany, or the Netherlands for PCR testing. They test positive. They return to Australia with documented diagnoses. They are still not treated under the Australian healthcare system, because the official DOH position has not changed. They pay out-of-pocket for everything.

Three legal vectors run in parallel. Australian Consumer Law (ACL) s. 18: A person must not, in trade or commerce, engage in conduct that is misleading or deceptive. The ACL extends to statutory bodies in their capacity as providers of information to the public. A government health department that publishes official guidance stating that Lyme disease does not exist in Australia — when its own national science agency has documented the pathogen in native ticks — is publishing materially false information. Patients rely on that information. They are harmed by it. ACL s. 18 applies. Civil Liability Act 2002 (NSW), s. 5B: A person who fails to take precautions against risk of harm is negligent if: the risk was foreseeable, the risk was not insignificant, and a reasonable person would have taken precautions. The DOH had access to the CSIRO research. A reasonable government department would have updated its official position when its own science agency documented the pathogen. The failure to do so is not merely a policy choice — it is a failure with documented, calculable harm to identifiable patients. ICESCR Art. 12: Australia is a signatory to the International Covenant on Economic, Social and Cultural Rights. Article 12 guarantees the right to the enjoyment of the highest attainable standard of physical and mental health. A government policy that officially denies a documented disease — preventing patients from receiving appropriate treatment within the national health system — violates Art. 12. The UN Special Rapporteur on the Right to Health is a parallel escalation path that builds the international record while domestic litigation proceeds.

The harm quantum for Australian Lyme patients is the largest of the four strategies because the diagnostic delay is the longest. While Ontario patients face average diagnostic delays of 6.7 years, Australian Lyme patients — who must travel internationally to receive a correct diagnosis — face average delays of 10.5 years. Ten and a half years of untreated infection, of out-of-pocket treatment costs, of income loss. Test case calculation (Blenus v. Fraser method, adapted for Australian jurisdiction): Patient earning $72,000 AUD annually at time of initial presentation. 10.5 years × $72,000 × 5% compound = $953,811 AUD. Add: international PCR testing costs ($4,000–$12,000 depending on destination), international specialist consultation ($2,000–$8,000), ongoing out-of-pocket treatment in Australia ($15,000–$40,000 per year for decade-long cases), travel costs. A conservative single-plaintiff quantum for a ten-year Australian Lyme misdiagnosis is AUD $1.2–1.8 million. The full Australian patient cohort — patients who received a negative diagnosis, later tested positive internationally, and have documented the intervening harm — numbers in the thousands. A government whose official policy created this harm is exposed to a class action of significant magnitude. The VLA15 vaccine (Pfizer/Valneva), approved in the EU in 2024, has not been approved in Australia in part because the official DOH position is that Lyme doesn't exist here. Patients are being denied prevention as well as treatment. The vaccine arm is a separate damages head: patients who would have been vaccinated but for the DOH's prevention of vaccine approval have an additional claim for every subsequent year of infection.

If the Department of Health and TGA engage with the brief and update the official position: the outcome is a revised policy that allows Australian patients to be diagnosed and treated within the national health system. All currently denied claims reopen. The vaccine approval proceeds. Class action is negotiated. If they refuse to engage: TC-AP-014. The MEEK protocol. This is not a threat — it is a documented sovereign enforcement mechanism. The brief is filed with the Federal Court of Australia. The ICESCR Article 12 complaint is filed simultaneously with the UN Special Rapporteur. The media record — CSIRO confirmation, DOH denial, patient harm — is public and builds the case that this is not a dispute about science but a refusal to acknowledge science. Steve Biko was clear about where power actually resides. Institutional authority depends on the willingness of those it governs to accept its pronouncements as true. When CSIRO publishes the tick data and the DOH ignores it, the institution has made a choice — and that choice is visible. The brief makes it visible in court. Sovereign enforcement makes it visible everywhere else.

This is the hardest of the four strategies — not because the evidence is weaker, but because the institutional resistance is stronger. The DOH has an entire bureaucratic apparatus defending a position that was never scientifically sound. Changing it requires more than a single court case. It requires a sustained, multi-vector campaign that makes the cost of maintaining the false position greater than the cost of changing it. The vectors are: Federal Court AU (ACL s. 18 + Civil Liability Act NSW), HRTO equivalent in Australia (AHRC — Australian Human Rights Commission), UN Special Rapporteur on the Right to Health, media (the CSIRO data is a story: government science contradicts government health policy, patients pay with a decade of their lives), and parliamentary inquiry (private members have tabled questions about Lyme in Australia since 2015 — the CSIRO data plus the patient harm record creates a parliamentary record). Each vector strengthens the others. A Federal Court filing creates news. News creates parliamentary questions. Parliamentary questions create internal DOH review. Internal review creates the opportunity for the official position to change without the government admitting it was ever wrong. We give them that offramp. But the offramp closes at TC-AP-014.